Radiotherapy for hepatocellular carcinoma gains a practical framework for patient selection and dose planning

A comprehensive review integrates randomized HCC radiotherapy evidence with practical recommendations for liver-function assessment, dose constraints, motion management and high-risk treatment.

KEY POINTS

  • This comprehensive review synthesizes contemporary evidence for external beam radiotherapy (EBRT) in hepatocellular carcinoma (HCC), including randomized comparisons, clinical guidelines, particle therapy, treatment planning and high-risk disease scenarios. It incorporates recommendations from BCLC 2026, EASL, AASLD, NCCN and ASTRO, positioning EBRT as a locoregional option for selected early-stage disease, patients unsuitable for embolization or ablation, and advanced disease requiring integrated local and systemic treatment. The proposed treatment algorithm is an expert-consensus framework rather than a formally validated decision rule.
  • Randomized trials support clinically meaningful local-control advantages for EBRT in selected HCC populations. In the TRENDY trial, two-year local control was 100% with SBRT versus 48% with drug-eluting bead TACE, while another randomized comparison found 92.7% versus 75.8% two-year local progression-free survival with SBRT versus radiofrequency ablation. In NRG/RTOG 1112, adding SBRT to sorafenib increased median overall survival from 12.3 to 15.8 months, although the unadjusted primary analysis did not reach its prespecified significance threshold (HR 0.77; one-sided p=0.06); progression-free survival improved from 5.5 to 9.2 months (HR 0.55; p<0.001).
  • Baseline hepatic reserve should guide treatment selection and prescription. Patients with Child-Pugh A and modified ALBI grade 1–2a are generally better candidates for ablative EBRT, whereas Child-Pugh B7 or worse or modified ALBI ≥2b requires individualized assessment. The authors emphasize that conventional dose constraints were largely developed in patients with preserved liver function and may not adequately protect patients with portal hypertension, thrombocytopenia or pre-existing hepatic decompensation.
  • Liver dose constraints should be adjusted to both prescription and functional reserve. Protocols such as RTOG 1112 allow 50 Gy in five fractions when mean liver-minus-GTV dose is ≤13 Gy, with prescription reductions when necessary. The review discusses more conservative risk-adapted objectives, including mean liver dose approximately 6–10 Gy for higher-risk patients and <6 Gy for the most vulnerable, while acknowledging that several preferred thresholds are consensus recommendations rather than prospectively validated limits for patients with severely impaired hepatic function.
  • Accurate target delineation and motion management are fundamental to safe liver radiotherapy. The authors recommend multiphasic CT supplemented by MRI, careful interpretation beyond arterial enhancement alone, and explicit accounting for previously ablated or nonfunctional liver regions. Respiratory gating, breath-hold or tracking should be selected according to tumor location and patient capability, while daily CBCT, MRI or fiducial-guided verification should assess both tumor-containing liver segments and adjacent gastrointestinal structures.
  • Several high-risk scenarios require anatomy- and function-adapted treatment. For tumors near the stomach or duodenum, adaptive radiotherapy may improve target coverage while protecting mobile gastrointestinal organs, although randomized outcome evidence remains unavailable. For macrovascular invasion, SBRT may be integrated with systemic treatment, while carbon-ion and proton therapy may be considered when their dose distributions meaningfully preserve uninvolved liver. The authors caution that the direct randomized comparison of protons and photons in NRG-GI003 had not demonstrated a survival advantage for protons in preliminary reported results.
  • Treatment sequencing and post-treatment management remain areas of uncertainty. Most evidence supporting combinations with systemic agents involves sequential rather than fully concurrent treatment, and the authors advise particular caution with anti-VEGF therapies such as bevacizumab near gastrointestinal SBRT. EBRT is also discussed as a potential bridge to liver transplantation and as a salvage option after previous locoregional treatment, but reirradiation requires careful cumulative OAR assessment and preservation of remaining functional hepatic tissue.

CLINICAL TAKEAWAY

EBRT, including SBRT and selected particle-therapy approaches, has a well-supported role in the multidisciplinary management of HCC and should be considered alongside ablation, embolization and systemic treatment rather than only after other options fail. The principal clinical challenge is appropriate patient selection and liver-function-adapted treatment planning, particularly in patients with impaired hepatic reserve or tumors adjacent to critical gastrointestinal structures.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction